Document Detail

Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
MedLine Citation:
PMID:  22713287     Owner:  NLM     Status:  Publisher    
AIMS: Cinaciguat (BAY 58-2667) is a soluble guanylate cyclase (sGC) activator that, in a previous study among patients with acute heart failure syndromes (AHFS), improved pulmonary capillary wedge pressure (PCWP) at the expense of significant hypotension at doses ≥200 µg/h. The aim of the COMPOSE programme was to investigate the safety and efficacy of fixed, low doses of intravenous cinaciguat (<200 µg/h for 24-48 h) as add-on to standard therapy in adults hospitalized with AHFS. METHODS AND RESULTS: COMPOSE comprised three randomized, double-blind, placebo-controlled studies in patients with [COMPOSE 1 and 2 (NCT01065077 and NCT01067859)] or without [COMPOSE EARLY (NCT01064037)] a requirement for invasive haemodynamic monitoring. COMPOSE 1 and COMPOSE EARLY assessed the effects of cinaciguat (50, 100, and 150 µg/h) on haemodynamics and dyspnoea, respectively. COMPOSE 2 assessed the haemodynamic effects of 10 and 25 µg/h cinaciguat. COMPOSE was terminated early due to an excess of non-fatal hypotension and recruitment difficulties. In COMPOSE 1 (n = 12), cinaciguat reduced PCWP at 8 h compared with placebo, but there was no relevant change in cardiac index. In COMPOSE EARLY (n = 62), no meaningful difference in dyspnoea was shown between cinaciguat and placebo. CONCLUSION: In this limited database, short-term use of intravenous cinaciguat decreased blood pressure without improving dyspnoea or cardiac index. Given the lack of effect on dyspnoea and cardiac index and the hypotensive effect seen even with low doses, it is doubtful that further studies with intravenous cinaciguat would prove beneficial in this patient population.
Mihai Gheorghiade; Stephen J Greene; Gerasimos Filippatos; Erland Erdmann; Roberto Ferrari; Phillip D Levy; Aldo Maggioni; Christina Nowack; Alexandre Mebazaa;
Related Documents :
2648017 - A modified formula of gik (glucose-insulin-potassium) therapy for treatment of extensiv...
8723857 - Isoflurane and halothane impair both systolic and diastolic function in the newborn pig.
8000277 - Effect of beta 1-adrenoceptor blockade in rats at 5 bar ambient pressure.
11114957 - Nitric oxide inhibition intensifies the depressant effect of cocaine on the left ventri...
15940357 - Awareness and misconception of hypertension in canada: results of a national survey.
15699467 - Genomic susceptibility loci for brain atrophy in hypertensive sibships from the genoa s...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-19
Journal Detail:
Title:  European journal of heart failure     Volume:  -     ISSN:  1879-0844     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Centre for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave., Suite 1006, Chicago, IL 60611, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The predictive values of beta1-adrenergic and M2 muscarinic receptor autoantibodies for sudden cardi...
Next Document:  Left ventricular dysfunction due to diffuse multiple vessel coronary artery spasm can be concealed i...